Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.59 |
| ▸ | ITGB3 | P05106 | 8/20 | 0.39 |
| ▸ | ITGA2B | P08514 | 8/20 | 0.39 |
| ▸ | ECE1 | P42892 | 1/20 | 0.37 |
| ▸ | GHSR | Q92847 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | CALCRL | Q16602 | 2/20 | 0.36 |
| ▸ | NMT2 | O60551 | 1/20 | 0.35 |
| ▸ | NMT1 | P30419 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3948444 | 1.00 | SLC15A2 (0.59) | SLC15A2ITGB3ITGA2BECE1GHSR | |
| SCHEMBL3948446 | 1.00 | SLC15A2 (0.59) | SLC15A2ITGB3ITGA2BECE1GHSR | |
| SCHEMBL29473319 | 0.97 | SLC15A2 (0.63) | SLC15A2ITGB3ITGA2BECE1GHSR | |
| SCHEMBL259085 | 0.96 | SLC15A2 (0.64) | SLC15A2ITGB3ITGA2BECE1GHSR | |
| SCHEMBL10595108 | 0.96 | SLC15A2 (0.64) | SLC15A2ITGB3ITGA2BECE1GHSR | |
| SCHEMBL259084 | 0.96 | SLC15A2 (0.64) | SLC15A2ITGB3ITGA2BECE1GHSR | |
| SCHEMBL5598418 | 0.96 | SLC15A2 (0.64) | SLC15A2ITGB3ITGA2BECE1GHSR | |
| SCHEMBL8832939 | 0.96 | SLC15A2 (0.64) | SLC15A2ITGB3ITGA2BECE1GHSR | |
| SCHEMBL2815080 | 0.95 | SLC15A2 (0.63) | SLC15A2ITGB3ITGA2BECE1GHSR | |
| SCHEMBL4589903 | 0.95 | SLC15A2 (0.63) | SLC15A2ITGB3ITGA2BECE1GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240150404-A1 | BICYCLIC PEPTIDYL INHIBITOR OF TUMOR NECROSIS FACTOR-ALPHA | OHIO STATE INNOVATION FOUNDATION | 2024-05-09 | — | — | US | disclosed |
| US-11859019-B2 | Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha | OHIO STATE INNOVATION FOUNDATION (US) | 2024-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11859019-B2 | Bicyclic peptidyl inhibitor of tumor necrosis factor-alpha | NFKBIA, TNFRSF1A, NFATC1 | SLC15A2 4372/4885ITGB3 4703/4885ITGA2B 4669/4885 |
| US-20240150404-A1 | BICYCLIC PEPTIDYL INHIBITOR OF TUMOR NECROSIS FACTOR-ALPHA | NFKBIA, TNFRSF1A, NFATC1 | SLC15A2 4372/4885ITGB3 4703/4885ITGA2B 4669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.